




Institute of Genetics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary
Transposon-based gene delivery vectors for gene therapy
Andrea Nagy, Gergely Imre, Lajos Mátés*
ABSTrACT                        The first gene therapy clinical trials were initiated more than two decades ago 
thanks to the previous development of viral vectors that allow high efficiency gene transfer 
into mammalian cells. Since then the application of viral gene transfer has been a successful 
treatment option for a variety of diseases. Hematopoietic stem cells (HSCs) represent the most 
frequently targeted cell population for the treatment of severe monogenic diseases as their gene 
therapeutic correction is a valid alternative to conventional HSC transplantation when a compat-
ible donor is not available. Indeed, viral gene transfer was successfully applied in HSC-based ex 
vivo gene therapy of the blood and immune systems, albeit several studies have exposed serious 
adverse effects that were caused by the therapeutic vector induced inappropriate activation 
of proto-oncogenes. After these failures, researchers have developed new types of randomly 
integrating vectors that have proven safer in preclinical studies, which is consistent with interim 
reports of clinical trials also foreshadowing that they potentially have an improved safety profile. 
This review focuses on new and clinically relevant DNA transposon-based gene delivery vectors, 
and compares their properties with those of the old and new generation viral vectors.
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introduction
Molecular genetic technologies have recently enabled a 
variety of novel therapeutic approaches to treat diseases by 
genetically modifying the cells of the patients, which are col-
lectively referred to as gene therapy procedures. The major 
motivation for gene therapy has been the need to develop 
novel treatments for diseases for which there is no effective 
conventional treatment available. Gene therapy involves 
approaches like adding a functional copy of a gene to cells 
that have only non-functional copies or activating cells of 
the immune system so as to aid killing of diseased cells, just 
to mention the most common ones. The first human gene 
therapy clinical trial was performed in 1989 by Rosenberg 
and co-workers (1990) in the USA. These investigators 
used a γ-retrovirus vector, an early derivative of Moloney 
murine leukemia virus (MLV), to introduce the neomycin 
resistance gene into human tumor-infiltrating lymphocytes. 
They then reinfused the modified lymphocytes into patients 
with metastatic melanoma. This study demonstrated that 
γ-retroviral gene transduction for human gene therapy was 
feasible. Following the pioneering study of Rosenberg and 
co-workers (1990) the number of approved gene therapy 
clinical trials increased each year consistently over the next 
decade, reaching an annual global value around 100 by 1999 
that was roughly maintained as an average annual number of 
approved trials during the last 15 years. By June 2014, 2076 
gene therapy clinical trials had been completed, were ongoing 
or had been approved in 36 countries worldwide, according 
to the database of the Journal of Gene Medicine (http://www.
wiley.com//legacy/wileychi/genmed/clinical/). During the 
first decade of the 2000s, the so far dynamic growth in the 
number of annually approved clinical trials has stopped due 
to that insertional oncogenesis having emerged as a major 
limitation in gene therapy protocols treating for primary im-
munodeficiencies (Farinelli et al. 2014). The long term out-
come of the clinical trial started in Paris at the Necker-Enfants 
Malades Hospital in 1999 for treating X-linked Severe Com-
bined Immunodeficiency (SCID-X1) well demonstrated that 
the integrating γ-retroviral gene delivery vectors frequently 
mediated activation of proto-oncogenes like LIM (Lin11, 
Isl-1, Mec-3) domain only 2 (LMO2) (Hacein-Bey-Abina et 
al. 2003). Gene therapy was initially successful at correcting 
immune dysfunction in 8 of the 9 SCID-X1 patients treated 
between March 1999 and April 2002, however 31-68 months 
after gene therapy acute lymphoblastic leukemia (ALL) 
developed in 4 of these 9 patients (Hacein-Bey-Abina et al. 
2008; Hacein-Bey-Abina et al. 2010). 
This serious issue raised new demands on the gene therapy 
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vectors on which the scientific world is currently trying to 
meet.
A promising new approach potentially avoiding inser-
tional oncogenesis is the application of site-directed nucleases 
instead of integrating gene delivery vectors. Site-directed nu-
cleases are exploited to induce double-strand breaks (DSBs) 
and the following action of the cell intrinsic DNA repair 
systems harnessing the administered repair partner DNA may 
introduce the desired changes to the targeted chromosomal lo-
cus. Artificial nucleases, such as zincfinger nucleases (ZFNs) 
and transcription activator-like effector nucleases (TALENs), 
and the RNA-guided endonuclease system (the clustered 
regularly interspaced short palindromic repeats (CRISPR) 
and CRISPR-associated (Cas) system) are those site-directed 
nucleases currently tested mainly in preclinical studies. Very 
recently a report of a clinical study demonstrated the safety 
and feasibility of autologous transplantation of CD4-enriched 
T cells undergone a genetic modification at the CCR5 gene 
locus by ZFN, into Human Immunodeficiency Virus (HIV) 
patients (Tebas et al. 2014). The purpose of this procedure was 
to induce acquired genetic resistance to HIV infection in an 
attempt to mimic the known inherited resistance displayed by 
persons with the CCR5-delta32 mutation (Liu et al. 1996). 
Still the overall efficiency of genetic modifications medi-
ated by site-directed nucleases is significantly lower as com-
pared to randomly integrating gene delivery vectors (Radecke 
et al. 2010). Therefore, making the more effective randomly 
integrating vectors safer is necessary for a number of gene 
therapy protocols. One important direction of improvements 
in randomly integrating vector design was to develop lenti-
virus based vectors. Lentiviruses like the HIV are complex 
retroviruses and in contrast to γ-retroviruses they are able to 
infect nondividing and terminally differentiated cells. This 
is their significant advantage compared to γ-retroviral vec-
tors. In addition to that, the development of self-inactivating 
(SIN) lentiviral vectors (Miyoshi et al. 1998) also increased 
their safety profile.
Transposon-based gene delivery vectors represent a prom-
ising new branch of randomly integrating vector development 
for gene therapy. They have some intrinsic advantages over 
viral vectors, and recently we have also been able to elevate 
their efficiency into the viral range. Here we will discuss 
the major drawbacks of integrating viral vectors and give an 
overview of the characteristics of those transposon systems 
that are already used or qualifying for use in gene therapy.
insertional oncogenesis
The successful introduction of therapeutic genes into target 
cells is a prerequisite for gene therapy. Furthermore, for 
achieving long-term gene expression and clinical benefit, 
integration of the therapeutic genes to the chromosomal DNA 
of the target cells is also required. 
From the early stages of gene therapy viral vectors rep-
resent the greater part of vehicles for transferring genes to 
human cells. This is due to their efficient infection rate and 
the ability to stably integrate therapeutic genes into the host 
genome. Most of the integrating viral vectors used for gene 
therapy originate from γ-retroviruses and more recently from 
lentiviruses (Ginn et al. 2013). They are characterized by an 
RNA genome. Their proviral complementary DNA is inserted 
to the host genome by the virus-derived reverse transcriptase 
and integrase (Kootstra and Verma, 2003). γ-retroviruses can 
only replicate in dividing cells as they cannot transmit their 
genome through nuclear pores. First generation γ-retroviral 
vectors were based on MLV containing intact long terminal re-
peats (LTRs) comprising strong promoter/enhancer elements 
driving the expression of therapeutic genes (Deichmann and 
Schmidt, 2013). Lentiviruses are complex retroviruses and 
most of the lentiviral vectors are HIV-1-based. Lentiviruses 
can also transduce non-dividing cells due to the nuclear 
import of their viral preintegration complex (Bukrinsky et 
al. 1993). These gene delivery vectors of viral origin 
inherit many intrinsic features from their parental viruses. 
In the early era of gene therapy, a nearly random integration 
pattern of viral vectors was expected (Stocking et al. 1993). 
In contrast, by now it is clear that viral integration is far from 
being random. MLV tends to integrate into regulatory regions 
of actively transcribed genes (eg. transcriptional start sites 
or CpG islands) (Cattoglio et al. 2010), whereas HIV-1 ap-
pears to be biased toward regions of active transcription by 
a mechanism driving its integrations to the outer shell of the 
nucleus in close proximity to the nuclear pores (Marini et al. 
2015; Schroder et al. 2002). Gene delivery vectors derived 
from MLV and HIV-1 also exhibit the same integration pat-
terns as their parental viruses (Fig. 1). 
Insertional mutagenesis is a natural consequence of such 
integrating vector insertions. In addition to the potential 
disruption of host genetic elements, an even more dangerous 
phenomenon, the transcriptional deregulation of genes near 
the sites of vector integration is also associated to insertional 
mutagenesis. This phenomenon is caused by the genetic 
elements present on the vector or on the cargo DNA. Virus 
specific transcriptional enhancers within the viral LTRs have 
been identified as one of the major determinants of nearby 
host gene activation independent of retrovirus subtypes, 
and the MLV LTR enhancer has been shown to exhibit the 
strongest activity in this respect (Montini et al. 2009). To 
decrease the strength of host gene activation and increase 
vector safety, SIN retroviral vectors were designed. In these 
vectors, enhancer/promoter sequences of the LTRs are re-
moved, thereby greatly reducing their potential of activating 
neighboring genes (Yu et al. 1986). Importantly, insertional 
host gene activation is also determined by the characteristics 
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of transcriptional regulatory elements carried in the cargo. 
However, the internal cellular promoters, generally used in 
the cargo to drive the expression of therapeutic genes, induce 
deregulation of host gene expression less frequently, at a 
shorter range and to a lower extent as compared to intact viral 
LTRs (Maruggi et al. 2009). 
Collectively, the biased viral integration patterns and the 
potential of the viral vectors to transcriptionally deregulate 
nearby genes raise the possibility of insertional oncogenesis 
driven by the most hazardous subset of insertional mutagen-
esis events. Indeed, insertional oncogenesis is currently the 
major limitation in classical gene therapy protocols using ran-
domly integrating gene delivery vectors. Clinical experience 
has shown that viral vectors typically activate the expression 
of nearby tissue specific proto-oncogenes, resulting in the 
clonal outgrowth of those transformed cells. The scientific 
community first realized this serious drawback in relation to 
gene therapy treatment of primary immunodeficiencies.
Initial gene therapy efforts with the use of integrating vec-
tors targeted primary immunodeficiency disorders. These are 
rare, inherited disorders caused by developmental defects of 
various cells of the immune system. The resulting impaired 
immune responses predispose patients to autoimmunity, 
infections and even tumorigenesis (Notarangelo, 2010). If 
the adverse consequences of an inherited genetic aberration 
are manifested in one of the early steps of hematopoietic 
lineage commitment, it leads to the complete lack or func-
tional impairment of blood cell subsets. This is the case with 
SCIDs. One of the most common types of SCID is SCID-X1 
which is caused by mutations in the X chromosomal gene 
coding for the interleukin-2 (IL-2) receptor common gamma 
chain (IL2RG). IL2RG is an important signaling component 
of many interleukin receptors directing the development 
and growth of lymphocytes. This monogenic disease is an 
excellent target of ex vivo gene therapy as delivery of a 
single corrected copy of IL2RG to autologous hematopoietic 
stem cells (HSCs) ensures successful reconstitution of the 
hematopoietic system following the transplantation of those 
genetically modified HSCs. High risk of γ-retroviral vector-
based gene therapy became clear when in clinical trials (led 
in France and the UK) 5 of 20 patients treated for SCID-X1 
developed T cell acute lymphoblastic leukemia (ALL) after 
infusion of autologous CD34+ T cells modified with the 
therapeutic MLV-based retroviral vector (Howe et al. 2008; 
Hacein-Bey-Abina et al. 2010). The causative relationship be-
tween the therapeutic vector and leukemia was confirmed as 
viral integrations were found near the promoter of the LMO2 
lymphoid proto-oncogene leading to its increased expression 
(Fig. 2). Insertion site analyses revealed viral integrations 
also near to Cyclin D2 (CCND2) and MECOM (MDS1and 
EVI1 complex locus). Moreover, several integration sites 
were found in close proximity to other cancer-associated 
genes like the HoxB cluster, High-mobility group AT-hook 2 
(HMGA2), jumonji, AT rich interactive domain 2 (JARID2) 
and Myeloid Cell Leukemia 1 (MCL1) (Hacein-Bey-Abina 
et al. 2003, 2010; Howe et al. 2008). This distribution of 
integration sites together with additional secondary genetic 
events led to the outgrowth of specific clones and finally leu-
kemogenesis. Similar outcomes were observed when chronic 
granulomatous disease (CGD) and Wiscott-Aldrich syndrome 
(WAS) were treated with γ-retrovirus-based vectors (Ott et 
al. 2006; Braun et al. 2014). The comprehensive analysis of 
γ-retroviral integration sites early after gene therapy generally 
revealed a polyclonal pattern of haematopoiesis. However, 
„clonally skewed” vector insertion profiles, where clones with 
insertions near proto-oncogenes are enriched, were becoming 
evident during the follow-up studies, finally leading to the 
development of leukemias (Hacein-Bey-Abina et al. 2010; 
Braun et al. 2014).
Lately the initial SCID-X1 clinical trial was repeated 
using a SIN-γ-retroviral vector (Hacein-Bey-Abina et al. 
2014). This new SIN-γ-retroviral vector was also based on 
MLV but the U3 enhancer was removed from the viral LTR 
and the expression of IL2RG gene was driven by the human 
elongation factor 1γ short promoter (Zychlinski et al. 2008; 
Hacein-Bey-Abina et al. 2014) (Fig. 2). In its other properties 
the new vector was similar to the one used in the previous 
trial. Genome analyses revealed that the distribution of vector 
Figure 1. Insertional site preference of integrating vectors in HSCs and 
HSC-derived cells. Due to the similar experimental design of the stud-
ies of Huang et al. (Huang et al. 2010) and Cattoglio et al. (Cattoglio 
et al. 2010) analyzing transposon and viral vector integration profiles 
respectively, the observed frequencies of different vector integra-
tions in RefSeq genes can be compared. Considering the known bias 
of γ-retroviral vector integrations towards 5’ regulatory regions, in 
addition to the integrations in RefSeq genes those viral integrations 
within ±50 kb from a known transcription start site (TSS) were as well 
determined as gene hits (Cattoglio et al. 2010). The random integration 
bar essentially indicates the gene content of the genome.
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integration sites was largely similar using the SIN-γ-retroviral 
vector to patients’ from the previous trial treated with the con-
ventional γ-retroviral vector (Hacein-Bey-Abina et al. 2014). 
Elevated frequency of insertions has been detected near tran-
scription start sites, gene-dense regions, and epigenetic marks 
associated with active transcription units. Thus, the alterations 
to the SIN-γ-retroviral vector did not have major effects on 
global associations of integration sites with these genomic 
features. However, “clonal skewing” has been less evident in 
the new clinical trial within the current observation period. 
Most importantly in the new SIN-γ-retroviral vector -based 
clinical trial, to date -with a median follow-up of 33 months- 
no serious adverse event occurred in the treated patients 
(Hacein-Bey-Abina et al. 2014). This suggests that removal 
of the viral enhancer reduced the potential of the γ-retroviral 
vector to transcriptionally activate nearby genes (Fig. 2).
Still the γ-retroviral and lentiviral genomic integration pat-
terns may include a potential risk for carcinogenesis (Fig. 1). 
Therefore, other gene delivery vectors with significantly safer 
genomic integration patterns and lower potential to transcrip-
tionally deregulate nearby genes are attractive alternatives of 
retroviral gene delivery.
General considerations supporting 
application of dNA transposons for gene 
therapy
In parallel with the development of safer viral vectors, alterna-
tive vector systems for gene therapy purposes are also under 
investigation. Among these, here we will focus on transposon-
based vector systems. 
Transposons are mobile genetic elements found in all eu-
karyotic genomes. Through their mobilization they are largely 
contributing to the diversity and evolution of host genomes 
(Prak and Kazazian 2000). Transposable elements can be clas-
sified into two major groups, such as DNA transposons and 
retrotransposons. Retrotransposons utilize “copy and paste” 
mechanism to spread in the host genome. The RNA interme-
diate of the element is reverse transcribed and inserted in a 
new genomic location. They have large evolutionary impact, 
and some of the currently active mammalian retrotransposons 
are also associated with human diseases (Belancio et al. 2008; 
Cordaux and Batzer 2009). Because of this and due to their 
Figure 2. The mechanism of inducing insertional oncogenesis by MLV-derived γ-retroviral vectors. (A) Near the LMO2 locus a typical integration 
site for the MLV-derived vectors is shown. (B) The MLV-derived γ-retroviral vector and its potential impact on the adjacent LMO2 gene. (C) The 
MLV-derived SIN γ-retroviral vector and its potential impact on the adjacent LMO2 gene. Both vectors carry the IL2RG therapeutic gene. LTR, long 
terminal repeat; pA, polyadenylation signal; light red arrows, cellular promoters (EF1alpha promoter in the case of the therapeutic construct); 
U3, R and U5, are transcriptional control elements of the viral LTRs, the U3 element represents strong promoter/enhancer activity.
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uncontrollable nature, retrotransposons are not good candi-
dates as gene delivery vehicles for therapeutic purposes. Here, 
we rather focus on DNA transposons which mostly move in 
the host genome through a “cut and paste” mechanism (Fig. 
3). Typically these elements are used for gene delivery in 
animal models and human gene therapy applications (Ivics 
et al. 2009). Their broad range of applicability is due to their 
simple genetic composition and easy handling as plasmid-
based gene delivery tools. Native DNA transposons typically 
contain a single gene coding for the transposase protein. This 
gene is flanked by two inverted terminal repeats (ITRs) which 
contain binding sites for the transposase. During the “cut and 
paste” mechanism of their transposition the transposase binds 
to the ITRs and catalyzes excision and subsequent integration 
of the element. An appealing feature of this system is that the 
transposase protein can act on any sequence flanked by the 
ITRs. In conventional DNA transposon-based vector systems 
the transposase source is separated from the gene of interest 
placed between the ITRs. This way any gene of interest can be 
introduced efficiently into the host genome and the system’s 
gene transfer activity is controlled and ensured by the trans-
supplemented transposase (Fig. 3). 
Therefore, gene therapy community has turned toward 
DNA transposons that share attractive features making 
them favorable tools for such applications. Some of their 
remarkable features designating them as a potentially better 
alternative than viral vectors for therapeutic gene delivery 
are mentioned below. 
Cargo capacity
During design of viral vectors the packaging limit of the used 
virus should be taken into account. Size of the therapeutic 
constructs is limited by the packaging capacity of the virus 
capsid. Both the previously mentioned γ-retroviral and lenti-
viral vectors have the cargo capacity of ~8 kb (Thomas et al. 
2003). In general, transposon-based vector systems can move 
larger genetic payload enabling the integration of complex or 
Figure 3. Schematic representation of the two-component DNA transposon-based gene delivery system and the mechanism of the ’cut and paste’ 
transposition of Sleeping Beauty and piggyBac transposons.  GOI, gene of interest; ITR, inverted terminal repeat; red arrow, promoter.
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multiple transgenes with a clinically relevant efficiency (Li 
et al. 2011; Turchiano et al. 2014) 
Immunogenicity
One of the aims while constructing gene delivery vectors is 
to prevent the triggering of the immune system. Throughout 
the years of their gene therapy usage, viral vectors have 
been extensively engineered to reduce their immunogenicity. 
Nearly all coding regions of the viral genome is deleted, only 
those have been left intact which play role in packaging and 
integration. In practice, those remaining ones are provided in 
trans for the production of recombinant viral particles (Blesch 
2004). Still, these systems need several viral proteins to func-
tion properly. These proteins have the potential to induce 
harmful immune-mediated and inflammatory responses.
 In this regard, transposons serve as good alternatives. 
They are circular plasmid DNA, they do not contain viral 
proteins, in fact, the only protein needed for their function 
is the transposase. Therefore, they are significantly less im-
munogenic as compared to viral vectors. Although cytotox-
icity can occur when applying transposon-based vectors due 
to the short-time transposase protein overexpression, this 
causes significantly lower immune response than the pres-
ence of viral helper proteins. Mechanisms of host response 
to non-viral vectors have not been completely elucidated. 
Toll-like receptor-9 (TLR-9) and DNA-dependent activator 
of interferon regulatory factors (DAI) are known to recognize 
unmethylated foreign DNA. These lead to sometimes overlap-
ping signaling pathways to induce immune response (Baccala 
et al. 2009; Sharma and Fitzgerald 2011). Knowing of these 
mechanisms in detail will further help in the construction of 
immunologically safer transposon-based vectors.
Integration site preference
As already mentioned in the first section, different viral vec-
tors prefer different genomic loci to integrate. γ-retroviral and 
lentiviral vectors show pronounced preference for integrating 
near to transcriptional start sites (Cattoglio et al. 2010) and 
into active transcriptional units (Schroder et al. 2002; Trono 
2003), respectively. Accumulating data available related to 
the molecular mechanism of integration site selection of viral 
vectors. Probably the best known viral integrase (IN)-cellular 
cofactor interaction is the lentiviral IN-lens epithelium-
derived growth factor (LEDGF) interaction which target len-
tiviral integration into active transcription units (Cherepanov 
et al. 2003) to the outer shell of the nucleus (Marini et al. 
2015). Recent studies identified a host cellular cofactor of 
MLV, bromodomain containing protein 2 (BRD2), a member 
of the bromodomain and extraterminal domain (BET) family 
of chromatin binding proteins (Gupta et al. 2013). The authors 
also showed that with small-molecule BET inhibitors MLV 
integration can be reduced in vivo, and integration site prefer-
ence can be shifted away from transcription start sites, thereby 
utilizing such an approach a safer MLV integration pattern 
may be achieved for gene therapeutic applications. 
As opposed to viral vectors some DNA transposons, such 
as Sleeping Beauty, show significantly less preference for 
active genes or 5’ regulatory regions in the genome (Fig. 1) 
(Yant et al. 2005; Wang et al. 2008), (see details in the next 
section). Although they exhibit a weak bias in integration 
site selection, the molecular determinants behind that are 
largely unknown.
Gene transfer efficiency
Among DNA transposons, predominantly members of the 
Tc1/mariner (Sleeping Beauty, Ivics et al. 1997) piggyBac 
(piggyBack, Ding et al. 2005) and hAT (Tol2, Urasaki et al. 
2006; TcBuster, Woodard et al. 2012) families are used for 
transgene integration purposes in mammalian cells. These 
systems are all useful tools for experimental gene delivery 
in mammalian cells or in embryos. However, the initial gene 
transfer efficiencies exhibited by them in clinically relevant 
primary cell types were not comparable to that of the viral 
systems.
In the last decade hyperactive versions of the DNA trans-
posons Sleeping Beauty and piggyBac have been developed 
exhibiting highly efficient gene transfer capabilities already 
reaching the viral efficiency range. Because of these and their 
numerous other useful features -detailed in the next sections-
Sleeping Beauty and piggyBac are the most promising tools 
for gene therapy applications.
As they originate from different phylogenetic background, 
their biological properties are as well different. Knowing 
these properties in detail provides a basis for choosing the 
best-suited transposon vector system for the given therapeutic 
application (Table 1).
The Sleeping Beauty transposon system
Sleeping Beauty (SB) is a Tc1/mariner element, that was 
reconstructed almost two decades ago from inactive salmonid 
fish transposon sequences (Ivics et al. 1997). Since then it 
has shown to be active in several vertebrate species. One of 
its favorable features for using in human gene therapy is that 
it has no close relatives in the human genome, therefore the 
trans-mobilization of related host elements can be ruled out 
(Prak and Kazazian 2000).
The minimal sequence requirement for SB integration is a 
TA dinucleotide (Vigdal et al. 2002). This is duplicated upon 
transposition. Excision of an integrated SB element results in 
3 bp 3´-overhangs. Repair of this overhang, together with the 
TA target site duplication, creates a characteristic transposi-
tion footprint (Fig. 3) (Liu et al. 2004). It was also shown that 
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target site selection is rather determined by DNA structure 
as SB insertion sites are associated with highly deformable 
sequences surrounding the TA dinucleotides (Geurts et al. 
2006).
Extensive studies on SB integration site preference re-
vealed that it shows no or weak preference for transcription 
units, it also does not prefer 5’ regulatory regions and most 
of its gene hits are localized in introns (Yant et al. 2005). As 
gene therapy applications require vectors with the least prefer-
ence for target genes to avoid insertional mutagenesis, SB is a 
promising system for such applications. However, despite the 
fairly random integration pattern, intragenic integrations can 
still occur holding the possible risk of genotoxicity. As it was 
already discussed in the case of viral vectors this is largely 
due to the strong promoter/enhancer activity of viral LTRs 
present in the therapeutic vectors. In contrast to the LTR of 
viral vectors, the ITRs of SB have very low intrinsic promoter 
/enhancer activity (Moldt et al. 2007). To further reduce the 
risk of insertional oncogenesis, generation of transposons 
capable of targeted integration into specific loci is desirable 
(Voigt et al. 2008). The main strategy for this is the fusion of 
sequence-specific DNA-binding domains to the transposase 
protein. Unfortunately, the activity of SB is largely compro-
mised upon such fusions both C- and N-terminally (Wilson 
et al. 2005; Ivics et al. 2007).
In order to achieve optimal transposition with SB, the 
amounts of the components of the transposon system should 
be carefully optimized. High concentration of the transpos-
ase protein leads to a phenomenon called “overproduction 
inhibition”, of which the exact molecular mechanism is not 
known. It is suggested that transposase proteins in excess are 
assembled in higher-order oligomers, or sequestrated in the 
cytoplasm or in nucleoli, thereby transposition activity is de-
creased (Lohe and Hartl 1996; Bire et al. 2013). In most com-
parison studies SB revealed the most prone to overproduction 
inhibition among the tested transposases (Grabundzija et al. 
2010; Bire et al. 2013). The proper amount of the transposase 
expressing construct depends on the cell type and transfec-
tion conditions, while the amount of the transposon vector 
is mainly dependent on the desired transgene copy number. 
These are needed to be optimized for every particular ap-
plication. 
As the transposition activity of the original SB transposase 
is not robust enough to make it suitable for gene therapy ap-
plications, large efforts were made to increase its efficiency. 
As a result SB100x has been generated by a high-throughput, 
in vitro molecular evolution (Mates et al. 2009). This hyper-
active transposase is 100-fold more potent than the original 
SB in HeLa cells. Since its creation it has been successfully 
applied for germline transgenesis purposes in rodents, (Katter 
et al. 2013; Ivics et al. 2014c) rabbits (Ivics et al. 2014b) and 
pigs (Ivics et al. 2014a) and for stable gene transfer in clini-
cally relevant cells (Mates et al. 2009; Jin et al. 2011). It is 
also widely used in human gene therapy applications (Singh 
et al. 2014) (see the next section). 
One limitation of the SB transposon system is the progres-
sive loss of its transposition efficiency with increasing cargo 
size (Karsi et al. 2001). Although recent studies demonstrate 
that the SB system is able to carry large transgenes, even 
bacterial artificial chromosomes (BACs) (Rostovskaya et 
al. 2012), under such conditions the reduced transposition 
efficiencies are not compatible with gene therapeutic use. 
Therefore, when large therapeutic constructs (>10 kb) are 
needed to apply, another transposon system with larger cargo 
capacity would be a better choice. 
The piggyBac transposon system
The piggyBac (PB) element is identified in the Cabbage 
Looper moth genome (Fraser et al. 1985). As it was found to 
be highly active in a wide range of insect species it has be-
come the generally used vector for the germline modification 
of insects belonging to various orders (Handler 2002). 
PB transposase targets TTAA tetranucleotide sequences 
without any structural requirement (Li et al. 2005) and exci-
sion of an integrated PB element frequently leaves behind 
Table 1. Main features of the DNA transposons Sleeping Beauty and PiggyBac.
Main characteristics Sleeping Beauty PiggyBac
Target sequence TA (Vigdal et al. 2002) TTAA (Fraser et al. 1996)
Integration site preference Fairly random (31-39% into genes) (Yant et 
al. 2005)
Transcriptional units (47-67% into genes) (Ding et al. 
2005; Burnight et al. 2012)
Footprint     C(A/T)GTA (Ivics et al. 1997) None (Elick et al. 1996)
Cargo size ~10 kb (Izsvak et al. 2000) ~100 kb (Li et al. 2011)
Hyperactive transposase SB100x (Mates et al. 2009) hyPBase (Yusa et al. 2011)
Overproduction inhibition Yes (Grabundzija et al. 2010) Less affected (Wilson et al. 2007; Grabundzija et al. 2010)
Transposase tagging Apparent efficiency drop (Wilson et al. 2005; 
Ivics et al. 2007)
No apparent efficiency drop (Owens et al. 2012)
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no footprint (Elick et al. 1996) (Fig. 3). PB on the genomic 
scale exhibits bias toward transcriptional start sites, CpG 
islands and actively transcribed loci (Ding et al. 2005). In 
case of the PB system, fusion of DNA-binding domains to 
the transposase may give the possibility of targeted insertion, 
as PB retains its transposition activity upon addition of such 
domains on both the 5’ and 3’ ends. Although the number of 
off-target integrations remained high, this may be a powerful 
approach to direct PB insertion to safe genomic loci (Owens 
et al. 2012). In most comparison studies with other transpos-
ases, PB exhibits the lowest sensitivity for overproduction 
inhibition even at high transposase concentrations (Wilson et 
al. 2007; Grabundzija et al. 2010). In contrast, a more recent 
study of Kolacsek et al. (2014) found PB more prone to over-
production inhibition then any of the SB variants tested.
The PB transposase has been modified in order to have 
optimal codon usage in mammalian cells and the new codon-
optimized transposase mPBase has been effectively used for 
transposition in mouse cells (Cadinanos and Bradley 2007). 
So far, the most hyperactive PB transposase is hyPB identified 
in a screen of a large mutant library in S. cerevisiae (Yusa et 
al. 2011). One of the favorable features of both mPBase and 
hyPB is that they can move large genetic cargos up to 100 kb 
(Li et al. 2011), making the PB system a good candidate for 
integration of large therapeutic constructs. 
PB has been successfully used for the reprogramming of 
mouse and human fibroblast cells to induce pluripotent stem 
cells (iPS) (Woltjen et al. 2009). Based on its characteristic 
that it does not leave footprints upon excision (Ding et al. 
2005), the reprogramming factors were even removed from 
iPS cells by re-expressing the transposase protein (Yusa et al. 
2009; Woltjen et al. 2011). 
What may be of concern in terms of potential insertional 
oncogenesis is that the PB ITRs have significant enhancer/
promoter activity. It was previously shown that the 5’ ITR 
of PB acts as a promoter and the 3’ ITR displays enhancer 
activity (Cadinanos and Bradley 2007; Shi et al. 2007; Wilson 
et al. 2007). Nevertheless, a recent study demonstrated that 
this promoter activity is directional and both activities can 
be isolated by using insulators (Saha et al. 2015). However, 
random integration of an insulator-containing vector can be 
detrimental if it blocks the interaction between an endogenous 
promoter and its critical enhancer. Therefore, application of 
insulator elements as safety precaution should be carefully 
considered. 
Another safety concern for clinical application of the PB 
system is that numerous PB ITR-like sequence containing 
DNA elements and domesticated PB transposase-like genes 
are present in the human genome. The presence of ∼2000 
PB-like DNA elements in the genome raises the question 
of whether there is a risk of genomic mobilization or rear-
rangement upon expression of the exogenously delivered PB 
transposase (Feschotte 2006). Lately it has been demonstrated 
that, it seems unlikely that expression of the PB transposase 
can induce endogenous element mobilization or genomic 
rearrangements, even though only a few of possible PB ITR-
like elements were directly investigated (Saha et al. 2015). 
Transposase domestication occurs when the host recruits 
the transposase or some of its protein domains encoded 
by a mobile element in order to perform cellular functions 
(Feschotte 2008). In the human genome 5 domesticated 
PB transposase-like genes, piggyBac transposable element 
derived 1-5 (PGBD1-5) are present (Sarkar et al. 2003). 
Among these, PGBD3 and 5 are under thorough investigation. 
PGBD3 has been resulted from the landing of a PB element 
to intron 5 of the human Cockayne syndrome Group B (CSB) 
gene, leading to the generation of a CSB-PiggyBac fusion 
protein expressed in Cockayne syndrome (Newman et al. 
2008). Whereas PGBD5 has found to be neural-specific and 
it may have played role in neural evolution (Pavelitz et al. 
2013). Presence of these domesticated elements may raise the 
possibility of protein-protein interaction with administered 
transposase proteins resulting in functional interference, a 
phenomenon whose existence has not yet been proved.
Current stage of transposon applications 
for gene therapy
The SB and PB DNA transposon systems have been studied 
extensively to treat both genetic and acquired diseases. They 
proved their efficiency both in vitro and in vivo gene trans-
fer in clinically relevant cell types and preclinical animal 
models. 
Successful preclinical studies with the SB system include: 
expression of human blood coagulation factor IX in factor 
IX-deficient mice (Yant et al. 2000); correction of murine 
tyrosinemia type I by delivering the functional human fumaryl 
acetoacetate hydrolase gene (FAH) (Montini et al. 2002); 
correction of junctional epidermolysis bullosa in human 
patient-derived cells (Ortiz-Urda et al. 2003); stable expres-
sion of insulin in the livers of diabetic mice (He et al. 2004); 
expression of blood coagulation factor VIII and factor IX and 
phenotypic correction in mouse hemophilia models (Ohlfest 
et al. 2005b; Hausl et al. 2010); correction of mucopolysac-
charidosis type I and VII in a mouse model (Aronovich et al. 
2007; Aronovich et al. 2009); correction of Fanconi anemia 
type C in human patient-derived cells (Hyland et al. 2011); 
long-term reduction of jaundice in Gunn rats (Wang et al. 
2009) and correction of lung allograft fibrosis in a rat model 
(Liu et al. 2006). Anti-cancer therapy with SB was also done 
in mice having intracranial human glioblastoma (Ohlfest 
et al. 2005a); gastrointestinal cancer (Bao et al. 2012) and 
osteosarcoma (Huang et al. 2012). 
PB was also successfully used in preclinical cancer cell 
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gene therapy approaches. It was applied for a gene-directed 
enzyme prodrug therapy to treat mouse ovarian cancer and 
human ovarian adenocarcinoma cells (Kang et al. 2009a, 
2009b), for treatment of B-lineage malignancies (Manuri et 
al. 2010) and for the generation of Epstein-Barr Virus (EBV)-
specific cytotoxic T-cells targeting Human Epidermal growth 
factor Receptor 2 (HER2) positive cancer cells (Nakazawa 
et al. 2011). It was also used for modeling treatment of α1-
antitrypsin deficiency (Burnight et al. 2012) and hemophilia 
A in mice (Matsui et al. 2014).
Among DNA transposons for the time being only the SB 
system is involved in clinical trials. The first clinical trial 
using the SB transposon system was launched in 2008 in the 
United States. The strategy involves targeting modified T-cells 
to tumor-associated antigens (TAAs). TAAs are present on 
the surface of tumor cells and not on healthy cells, thereby 
specific recognition and destruction of the tumor cells is pos-
sible. Both autologous and allogeneic T-cells are used for ex 
vivo modification, during which a transposon vector carrying 
a chimeric antigen receptor (CAR) gene specific for a TAA is 
stably introduced into their genome, to produce the CAR T-
cells. Currently, there are eight ongoing phase-I clinical trials 
in the United States involving CAR T-cells generated with the 
SB system to treat different malignancies (http://www.wiley.
com//legacy/wileychi/genmed/clinical/). Most of the ongoing 
clinical trials are aiming to treat B-lymphoid malignancies by 
CAR T-cells targeting the B-cell antigen CD19. On the basis 
of initial clinical data next generation clinical trials can be 
planned. Recent studies attempt to increase transpositional 
efficiency by using the hyperactive SB100X transposase and 
to further decrease possible genotoxicity caused by the con-
tinuous transposase expression by using in vitro-transcribed 
mRNA as the transposase source. Furthermore, another 
approach is under development with which T-cells from a 
healthy donor can be pre-prepared to express CARs which 
can largely broaden the human application of CAR T-cells 
(Singh et al. 2014).
A European project led by the University of Geneva is also 
moving towards clinical trials targeting age-related macu-
lar degeneration (AMD). Scientist within the TargetAMD 
research network (http://www.targetamd.eu/) are aiming to 
develop an SB transposon-based gene therapy for the treat-
ment of the exudative form of AMD. This disease causes 
vision loss due to abnormal vascularization of the retina. 
This process is stimulated by increased levels of vascular 
endothelial growth factor (VEGF) and can be inhibited by 
the induction of pigment epithelium-derived factor (PEDF) 
which is an anti-angiogenic protein (Holekamp et al. 2002). 
Overexpression of the latter protein in modified cells is ex-
pected to restore VEGF/PEDF balance, thereby suppressing 
neovascularization of the retina and providing a long-term 
cure for exudative AMD. The therapeutic approach comprises 
the subretinal transplantation of autologous retinal pigment 
epithelial cells modified with an SB transposon vector carry-
ing the recombinant PEDF gene. Therapeutic gene delivery 
is achieved using the SB100X hyperactive transposase as it 
has been previously shown to mediate effective and stable 
transgene delivery into ARPE19 cells, as well as into primary 
retinal and iris pigment epithelial cells (Johnen et al. 2012). 
Very recently, by applying this SB-mediated PEDF transgene 
delivery into retinal pigment epithelial cells before their trans-
plantation, the corneal neovascularization was significantly 
reduced in a rabbit model of AMD (Kuerten et al. 2015).
Concluding remarks
Development of the field of gene therapy brought up numer-
ous efficient and promising treatment opportunities giving 
hope to cure diseases that have proven to be incurable by con-
ventional treatments. The majority of gene therapy protocols 
require efficient delivery of therapeutic genes into relevant 
target cells, followed by their robust chromosomal integra-
tion for long-term expression and clinical benefit. Clinical 
trials treating primary immunodeficiencies with retroviral 
vectors demonstrated efficient gene transfer and correction 
of the immunodeficiency (Farinelli et al. 2014). After the 
initial success, however, their long-term clinical outcome 
highlighted the risk of adverse effects associated to therapeu-
tic gene delivery (Farinelli et al. 2014). It became clear that 
retroviral vectors typically activated the expression of nearby 
tissue specific proto-oncogenes, resulting in insertional on-
cogenesis. This called for the development of nonviral gene 
delivery vectors with significantly safer integration patterns 
and lower potential to transcriptionally deregulate nearby 
genes. Recently, SB and PB transposon-based vectors, ef-
ficient enough in mammalian cells, represent a promising 
new toolkit of randomly integrating vectors for gene therapy 
(Mates et al. 2009; Yusa et al. 2011). It is not yet known 
whether their attractive features will indeed be translated to an 
improved safety profile of gene therapy protocols. However, 
it should be emphasized that so far neither of the SB and PB 
vectors exploited for preclinical applications has provided any 
evidence of triggering insertional oncogenesis (Montini et al. 
2002; Hausl et al. 2010; Matsui et al. 2014).
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